Watch AEON. Know when insiders buy.
One email the day a filing lands. Free.
Work order
33
FLAG · insiders 66, shorts 0
Insiders, 90 days
+$243K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $12MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$54.6MNET CASH —52W 0.19 – 1.40SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$5.9M | −$1.2M | — | -0.02 | −$3.7M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$5.9M | −$11.8M | −229.7% | -0.29 | −$2.6M | — | — | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$5.5M | −$37.1M | −1883.7% | -3.72 | −$4.7M | $0 | −$4.7M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$2.5M | −$4.5M | — | -0.39 | −$2.6M | $0 | −$2.6M | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$4.3M | −$6.6M | −104.0% | -0.60 | −$2.1M | $0 | −$2.1M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$462K | $9.1M | — | 2.28 | −$7.9M | $4K | −$7.9M | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$2.3M | $2.1M | — | 3.40 | −$621K | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$4M | −$6.2M | — | -11.24 | −$3M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | $153.5M | $164.1M | — | 304.00 | −$8.1M | — | — | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$74.2M | −$118M | — | -227.87 | −$8.6M | — | — | May 14 |
| Q2 2023 · Jun 30 | — | — | — | −$14M | −$15.4M | — | -0.11 | −$10.1M | — | — | Aug 12 |
| Q1 2023 · Mar 31 | — | — | — | −$13M | −$17.6M | — | -0.13 | −$11.1M | — | — | May 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$12.8M | −$39.2M | — | -3.95 | −$17.3M | $4K | −$17.3M | — | — |
| FY2024 · to Dec 31 | — | — | $73M | $42M | — | 72.93 | −$20.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$48.4M | −$52.6M | — | -0.38 | −$35.6M | $306K | −$35.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$1.9M | $8.2M | — | — | −$1.5M | — | — | — | — |
Every number comes from AEON Biopharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.